차세대 시퀀싱 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global next generation sequencing market size is expected to reach USD 41.91 Billion in 2034 from USD 12.96 Billion in 2025, growing at a CAGR of 13.93% during 2026-2034.This market is expanding as genomic sequencing becomes increasingly important across research, clinical diagnostics, precision medicine, drug development, and biotechnology. Next generation sequencing allows large volumes of genetic information to be analyzed more efficiently than many traditional sequencing approaches. Growing interest in understanding disease mechanisms and identifying genetic variations is encouraging adoption across healthcare and life-science applications. According to the National Human Genome Research Institute, next generation sequencing technologies have transformed genomic research by enabling researchers to sequence DNA at much greater scale and speed. This technological progress is creating opportunities across increasingly diverse genomic applications.

The next generation sequencing market is being driven by improvements in sequencing accuracy, throughput, automation, bioinformatics, and sample preparation. Researchers and healthcare providers are increasingly using sequencing to investigate inherited disorders, cancer-related mutations, infectious diseases, and other biological conditions. Sequencing is also becoming more relevant to pharmaceutical research, where genomic information can support biomarker discovery and patient stratification. Cloud-based analysis and advanced computational tools are making large sequencing datasets easier to process and interpret. As sequencing workflows become more integrated, providers are focusing on complete solutions covering instruments, consumables, software, data analysis, and laboratory services.

Future prospects remain strong as sequencing technologies become more accessible and applications expand beyond specialized research environments. Precision medicine is expected to remain an important opportunity, particularly as clinicians increasingly use molecular information to guide selected diagnostic and treatment decisions. Liquid biopsy, population genomics, infectious-disease surveillance, and agricultural genomics can provide additional growth avenues. Lower sequencing costs and simplified workflows could broaden adoption among smaller laboratories and healthcare institutions. Companies that combine high-quality sequencing platforms with robust bioinformatics, automation, data interpretation, and secure information management are likely to benefit from the continued expansion of genomic applications.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type of Sequencing

• Whole Genome Sequencing
• Targeted Resequencing
• Whole Exome Sequencing
• RNA Sequencing
• ChIP Sequencing
• De Novo Sequencing
• Methyl Sequencing

By Product Type

• Instruments
• Reagents and Consumables
• Services

By Application

• Drug Discovery and Personalized Medicine
• Genetic Screening
• Diagnostics
• Agriculture and Animal Research
• Other Applications (Epigenomics, Metagenomics, Transcriptomics)

By End User

• Hospitals and Healthcare Institutions
• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies

COMPANIES PROFILED

• 10x Genomics Inc., Agilent Technologies Inc., BGI Genomics Co. Ltd., Bio-Rad Laboratories Inc., Element Biosciences Inc., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Fulgent Genetics Inc., Guardant Health Inc., Illumina Inc., Macrogen Inc., Oxford Nanopore Technologies Plc, Pacific Biosciences of California Inc., PerkinElmer Inc., QIAGEN N.V., Singular Genomics Systems Inc., SOPHiA GENETICS SA, Thermo Fisher Scientific Inc., Twist Bioscience Corp., Ultima Genomics Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NEXT GENERATION SEQUENCING MARKET: BY TYPE OF SEQUENCING 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type Of Sequencing
• 4.2. Whole Genome Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Targeted Resequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Whole Exome Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. RNA Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. ChIP Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. De Novo Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Methyl Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NEXT GENERATION SEQUENCING MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product Type
• 5.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Reagents and Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. By Application Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Drug Discovery and Personalized Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Genetic Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Agriculture and Animal Research Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Other Applications (Epigenomics, Metagenomics, Transcriptomics) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NEXT GENERATION SEQUENCING MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals and Healthcare Institutions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Pharmaceutical and Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL NEXT GENERATION SEQUENCING MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type Of Sequencing
  • 7.2.2 By Product Type
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type Of Sequencing
  • 7.3.2 By Product Type
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type Of Sequencing
  • 7.4.2 By Product Type
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type Of Sequencing
  • 7.5.2 By Product Type
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type Of Sequencing
  • 7.6.2 By Product Type
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL NEXT GENERATION SEQUENCING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 10x Genomics Inc
  • 9.2.2 Agilent Technologies Inc
  • 9.2.3 BGI Genomics Co. Ltd
  • 9.2.4 Bio-Rad Laboratories Inc
  • 9.2.5 Element Biosciences Inc
  • 9.2.6 Eurofins Scientific SE
  • 9.2.7 F. Hoffmann-La Roche Ltd
  • 9.2.8 Fulgent Genetics Inc
  • 9.2.9 Guardant Health Inc
  • 9.2.10 Illumina Inc
  • 9.2.11 Macrogen Inc
  • 9.2.12 Oxford Nanopore Technologies Plc
  • 9.2.13 Pacific Biosciences Of California Inc
  • 9.2.14 PerkinElmer Inc
  • 9.2.15 QIAGEN N.V
  • 9.2.16 Singular Genomics Systems Inc
  • 9.2.17 SOPHiA GENETICS SA
  • 9.2.18 Thermo Fisher Scientific Inc
  • 9.2.19 Twist Bioscience Corp
  • 9.2.20 Ultima Genomics Inc